Sara M. Haserlat

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

Patricia L. Harris, D. Louis, D. Christiani, 2004, The New England journal of medicine.

Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials.

Patricia L. Harris, G. Giaccone, M. Kris, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mutations in the neutral sphingomyelinase gene SMPD3 implicate the ceramide pathway in human leukemias.

A. Look, D. Haber, D. Bell, 2008, Blood.

Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts

Patricia L. Harris, D. Altshuler, O. Olopade, 2007, International journal of cancer.

Epidermal Growth Factor Receptor Kinase Domain Mutations in Esophageal and Pancreatic Adenocarcinomas

Janusz Jankowski, David Ferry, Patricia L. Harris, 2006, Clinical Cancer Research.

Response of Some Head and Neck Cancers to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors May Be Linked to Mutation of ERBB2 rather than EGFR

Patricia L. Harris, D. Sgroi, D. Haber, 2005, Clinical Cancer Research.

Prevalence and Functional Analysis of Sequence Variants in the ATR Checkpoint Mediator Claspin

B. Henderson, Jianmin Zhang, D. Sgroi, 2009, Molecular Cancer Research.

CTX-8573, an Innate-Cell Engager Targeting BCMA, is a Highly Potent Multispecific Antibody for the Treatment of Multiple Myeloma

Michael M. Schmidt, A. Oliphant, P. Bobrowicz, 2019, Blood.

Abstract 4972: Preclinical development of a first-in-class NKp30xBCMA NK cell engager for the treatment of multiple myeloma

A. Oliphant, P. Bobrowicz, Sara M. Haserlat, 2019, Immunology.

Frequent met oncogene amplification in a Brca1/Trp53 mouse model of mammary tumorigenesis.

L. Chin, M. Rivera, C. Deng, 2006, Cancer research.